Sio Capital Management, LLC Cyma Bay Therapeutics, Inc. Transaction History

Sio Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.72 - $3.39 $11,573 - $22,811	-6,729 Reduced 1.2%	555,610 $1.64 Million
Q1 2021 May 14, 2021	SELL	$4.23 - $6.55 $105,750 - $163,750	-25,000 Reduced 4.26%	562,339 $2.55 Million
Q4 2020 Feb 16, 2021	SELL	$5.73 - $9.03 $3.28 Million - $5.16 Million	-571,897 Reduced 49.33%	587,339 $3.37 Million
Q3 2020 Nov 16, 2020	SELL	$3.32 - $7.24 $3.79 Million - $8.26 Million	-1,140,746 Reduced 49.6%	1,159,236 $8.39 Million
Q2 2020 Aug 14, 2020	BUY	$1.41 - $4.25 $3.06 Million - $9.21 Million	2,167,508 Added 1636.18%	2,299,982 $8.03 Million

Q1 2020 May 15, 2020	BUY	$1.25 - $2.02 $165,592 - $267,597	132,474 New	132,474 $196,000
Q2 2019 Aug 14, 2019	SELL	$6.05 - $13.66 $1.45 Million - $3.28 Million	-239,827 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$8.16 - $13.42 $428,400 - $704,550	52,500 Added 28.03%	239,827 $3.19 Million
Q4 2018 Feb 14, 2019	BUY	$6.54 - $11.74 $1.23 Million - $2.2 Million	187,327 New	187,327 $1.47 Million
Q4 2017 Feb 14, 2018	SELL	$7.67 - $9.31 $575,250 - $698,250	-75,000 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$5.95 - $8.26 $446,250 - $619,500	75,000	75,000 $605,000

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Sio Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sio Capital Management, LLC with notifications on news.